Shares of Viking Therapeutics (VKTX) lost 18% yesterday after pharma giant Merck (MRK) announced its foray into the obesity space. On Wednesday, Merck announced that it has secured a licensing deal for China-based Hansoh Pharma's investigational weight-loss drug. More on MRK's Drug Deal Per the terms of the deal, Merck will obtain exclusive rights to develop and market HS-10535, a preclinical oral small-molecule GLP-1 receptor agonist targeting metabolic disorders, including obesity. Hansoh will receive an ...

Viking Therapeutics Inc. VKTX is nearing a pivotal moment as its stock hovers just above a potential death cross.This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal. While not confirmed yet, the trajectory suggests growing pressure on the stock, which has struggled in recent months despite earlier rallies. Chart created using Benzinga ProRead Also: Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss DrugsVKTX ...

Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.In the third quarter, Griffin and Citadel more than tripled its stake in Viking Therapeutics (VKTX 1.86%). Griffin isn't the only one enthusiastic about this clinical-stage drugmaker. Wall Street analysts are sticking their necks out and predicting big gains around the corner.Recently, B. Riley analyst Mayank Mamtani initiated coverage of Viking Therapeutics with a buy rating. ...

It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX) . Shares have lost about 29.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Viking Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Narrower-Than-Expecte ...

Shares of Viking Therapeutics (VKTX) have lost nearly 17% in the past month, translating to about $1.2 billion in market value, compared with the industry’s 7.1% decline. The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. VKTX’s shares are trading below the 50 and 200-day moving averages.VKTX Stock Underperforms Industry, Sector & S&P 500 Image Source: Zacks Investment ResearchThough this biotech’s progress with its obesity drug program has been ...

On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred to as metabolic dysfunction-associated steatohepatitis, MASH) at the American Association for the Study of Liver Disease.Reduction in Liver Fat Content at 52 Weeks: Patients receiving VK2809 demonstrated statistically significant reductions in liver fat at Week 12, the primary endpoint.Patients receiving VK2809 ...

Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary EndpointsData Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and SafetySAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel ...

There aren't many biotechs that are more exciting than Viking Therapeutics (VKTX -7.45%) right now. Thanks to its clinical-stage candidate for weight loss, there's a real chance that this competitor could see its shares soar for years.But that doesn't mean you should rush to buy the stock without understanding what else is going on with this stock and why it's making the changes it's making. Let's examine three things you'll need to factor into your decision if you plan on investing in Viking Therapeutics t ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (VKTX -7.45%), a mid-cap biotech that rose in prominence this year. The drugmaker's shares are up by nearly 200% since January.However, while many investors are excited about Viking's prospects, others worry they have already missed the boat. How much upside does a clinical-stage biotech with a market cap of $6.3 billion have? Is it too late to invest in Viking Therapeutics, or do the company's shares rem ...

Mergers and acquisitions could make a comeback with Trump headed back to Washington.The 2024 presidential election and President-elect Donald Trump is headed back to Washington. The Republican party also won control of the Senate and the House of Representatives.If Trump's previous tenure in the Oval Office is an indicator for what can be expected, there's a good chance for a less stringent regulatory environment.One of my big predictions under a Trump presidency is that mergers and acquisitions (M&A) will ...